Cyclooxygenases: structural, cellular, and molecular biology.

Area of Science:

• Biochemistry
• Enzymology
• Pharmacology

Background:

• Prostaglandin endoperoxide H synthases (PGHS-1 and PGHS-2), also known as cyclooxygenases (COX-1 and COX-2), catalyze essential steps in prostaglandin synthesis.
• These enzymes are the primary targets of nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin and ibuprofen.
• NSAID inhibition of PGHSs offers therapeutic benefits such as reduced inflammation, pain, fever, and prevention of thrombotic events, colon cancer, and Alzheimer's disease.

Purpose of the Study:

• To review the structural basis of PGHS-1 and PGHS-2 catalysis.
• To elucidate how structural differences in PGHS-2 lead to selective inhibition by COX-2 inhibitors.
• To examine the evidence for independent signaling pathways mediated by PGHS-1 and PGHS-2.

Main Methods:

• Structural analysis of PGHS-1 and PGHS-2 enzymes.
• Mechanistic studies of cyclooxygenase and peroxidase activities.
• Review of pharmacological data on NSAID interactions with PGHS isoforms.
• Examination of gene expression regulatory mechanisms for PGHS-2.

Main Results:

• Enzyme structures correlate with cyclooxygenase and peroxidase catalytic mechanisms.
• Structural variations in PGHS-2 explain its differential sensitivity to COX-2 inhibitors.
• Evidence supports independent signaling roles for PGHS-1 and PGHS-2.
• Complex regulatory mechanisms govern PGHS-2 gene expression.

Conclusions:

• Understanding PGHS structure-function relationships is crucial for drug development.
• Differential inhibition of PGHS isoforms offers targeted therapeutic strategies.
• Further research into PGHS signaling and regulation may reveal new therapeutic avenues.